With a market cap of nearly $16 billion, the generic drugmaker Viatris (NASDAQ: VTRS) is minuscule in comparison to the profitable pharma titan AbbVie's (NYSE: ABBV) $228 billion. But, with Viatris' revenue growth starting to take off just as AbbVie's is decelerating, the fact that the smaller company is currently unprofitable may not deter investors.
And, since each company is in the midst of transitionary periods that are unprecedented, the risks of investing in either are higher than they'd normally be. Let's consider the merits of these stocks to weigh the chances of success moving forward.
Image source: Getty Images.
Source Fool.com